Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Mounjaro

Mounjaro 2.5 mg solution for injection in pre-filled pen Mounjaro 5 mg solution for injection in pre-filled pen Mounjaro 7.5 mg solution for injection in pre-filled pen Mounjaro 10 mg solution for injection in pre-filled pen Mounjaro 12.5 mg solution for injection in pre-filled pen Mounjaro 15 mg solution for injection in pre-filled pen Mounjaro 2.5 mg solution for injection in vial Mounjaro 5 mg solution for injection in vial Mounjaro 7.5 mg solution for injection in vial Mounjaro 10 mg solution for injection in vial Mounjaro 12.5 mg solution for injection in vial Mounjaro 15 mg solution for injection in vial Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 11

HOS-148199 · Präparat HOS-099850

Small mean increases in PR interval were observed with tirzepatide when compared to placebo (mean increase of 1.4 to 3.2 msec and mean decrease of 1.4 msec respectively). No difference in arrhythmia and cardiac conduction disorder treatment emergent events were observed between tirzepatide 5 mg, 10 mg, 15 mg and placebo (3.8 %, 2.1 %, 3.7 % and 3 % respectively).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.